Your browser doesn't support javascript.
loading
EVI1 dysregulation: impact on biology and therapy of myeloid malignancies.
Birdwell, Christine; Fiskus, Warren; Kadia, Tapan M; DiNardo, Courtney D; Mill, Christopher P; Bhalla, Kapil N.
Afiliación
  • Birdwell C; Division of Cancer Medicine, Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030, USA.
  • Fiskus W; Division of Cancer Medicine, Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030, USA.
  • Kadia TM; Division of Cancer Medicine, Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030, USA.
  • DiNardo CD; Division of Cancer Medicine, Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030, USA.
  • Mill CP; Division of Cancer Medicine, Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030, USA.
  • Bhalla KN; Division of Cancer Medicine, Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030, USA. kbhalla@mdanderson.org.
Blood Cancer J ; 11(3): 64, 2021 03 22.
Article en En | MEDLINE | ID: mdl-33753715
ABSTRACT
Ecotropic viral integration site 1 (Evi1) was discovered in 1988 as a common site of ecotropic viral integration resulting in myeloid malignancies in mice. EVI1 is an oncogenic zinc-finger transcription factor whose overexpression contributes to disease progression and an aggressive phenotype, correlating with poor clinical outcome in myeloid malignancies. Despite progress in understanding the biology of EVI1 dysregulation, significant improvements in therapeutic outcome remain elusive. Here, we highlight advances in understanding EVI1 biology and discuss how this new knowledge informs development of novel therapeutic interventions. EVI1 is overexpression is correlated with poor outcome in some epithelial cancers. However, the focus of this review is the genetic lesions, biology, and current therapeutics of myeloid malignancies overexpressing EVI1.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide / Proteína del Locus del Complejo MDS1 y EV11 Límite: Animals / Humans Idioma: En Revista: Blood Cancer J Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide / Proteína del Locus del Complejo MDS1 y EV11 Límite: Animals / Humans Idioma: En Revista: Blood Cancer J Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos
...